A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

April 15, 2022

Study Completion Date

June 10, 2022

Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
DRUG

CBP-201

CBP-201 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (68)

2002

Connect Investigative Site 503, Kyiv

3049

Connect Investigative Site 502, Kyiv

3057

Connect Investigative Site 505, Kyiv

10461

Connect Investigative Site 113, The Bronx

14618

Connect Investigative Site 105, Rochester

21162

Connect Investigative Site 110, White Marsh

23507

Connect Investigative Site 118, Norfolk

27103

Connect Investigative Site 117, Winston-Salem

28040

Connect Investigative Site 601, Madrid

29425

Connect Investigative Site 108, Charleston

30001

Connect Investigative Site 311, Taiyuan

33135

Connect Investigative Site 114, Miami

33155

Connect Investigative Site 109, Miami

33613

Connect Investigative Site 116, Tampa

35205

Connect Investigative Site 130, Birmingham

36038

Connect Investigative Site 506, Poltava

38119

Connect Investigative Site 107, Memphis

40205

Connect Investigative Site 132, Louisville

41009

Connect Investigative Site 603, Seville

43005

Connect Investigative Site 504, Lutsk

43235

Connect Investigative Site 133, Columbus

45229

Connect Investigative Site 123, Cincinnati

49006

Connect Investigative Site 501, Dnipropetrovsk

60637

Connect Investigative Site 111, Chicago

60657

Connect Investigative Site 126, Chicago

61124

Connect Investigative Site 509, Kharkiv

63141

Connect Investigative Site 127, St Louis

74136

Connect Investigative Site 112, Tulsa

74137

Connect Investigative Site 122, Tulsa

75092

Connect Investigative Site 101, Sherman

75231

Connect Investigative Site 104, Dallas

75759

Connect Investigative Site 106, Austin

76000

Connect Investigative Site 507, Ivano-Frankivsk

Connect Investigative Site 508, Ivano-Frankivsk

Connect Investigative Site 510, Ivano-Frankivsk

77074

Connect Investigative Site 120, Houston

84790

Connect Investigative Site 129, St. George

90048

Connect Investigative Site 134, Los Angeles

90503

Connect Investigative Site 119, Torrance

91942

Connect Investigative Site 125, La Mesa

92592

Connect Investigative Site 128, Temecula

93301

Connect Investigative Site 124, Bakersfield

98225

Connect Investigative Site 115, Bellingham

110004

Connect Investigative Site 313, Shenyang

200031

Connect Investigative Site 301, Shanghai

201620

Connect Investigative Site 312, Shanghai

210029

Connect Investigative Site 306, Nanjing

225007

Connect Investigative Site 308, Yangzhou

233060

Connect Investigative Site 307, Bengbu

266033

Connect Investigative Site 304, Qingdao

310014

Connect Investigative Site 310, Hangzhou

400042

Connect Investigative Site 303, Chongqing

434020

Connect Investigative Site 309, Jingzhou

530021

Connect Investigative Site 302, Nanning

710061

Connect Investigative Site 305, Xi’an

48109-0360

Connect Investigative Site 121, Ann Arbor

08540

Connect Investigative Site 102, Princeton

85-605

Connect Investigative Site 401, Bydgoszcz

30-033

Connect Investigative Site 407, Krakow

31-411

Connect Investigative Site 402, Krakow

59-300

Connect Investigative Site 409, Lubin

00-892

Connect Investigative Site 408, Warsaw

02-793

Connect Investigative Site 403, Warsaw

35-055

Connect Investigative Site 405, Rzeszów

15-879

Connect Investigative Site 404, Bialystok

41-800

Connect Investigative Site 406, Zabrze

08208

Connect Investigative Site 604, Barcelona

Unknown

Connect Investigative Site 602, Córdoba

Sponsors
All Listed Sponsors
lead

Connect Biopharm LLC

INDUSTRY

NCT04783389 - A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps | Biotech Hunter | Biotech Hunter